Safety and Efficacy of VDPHL01 in Males With AGA (NCT06972264)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects With Androgenetic Alopecia
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).
Who can join: Review the eligibility criteria below.
Location: Site 73 — Birmingham, Alabama
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (44 Sites)
Showing the first 25 of 44 sites.
- Site 73 — Birmingham, Alabama
- Site 89 — Birmingham, Alabama
- Site 77 — Phoenix, Arizona
- Site 69 — Encino, California
- Site 64 — Manhattan Beach, California
- Site 93 — Northridge, California
- Site 66 — Santa Monica, California
- Site 94 — Thousand Oaks, California
- Site 71 — Boca Raton, Florida
- Site 86 — Coral Gables, Florida
- Site 62 — Coral Gables, Florida
- Site 99 — Miami, Florida
- Site 54 — Ocala, Florida
- Site 96 — Tamarac, Florida
- Site 90 — Sandy Springs, Georgia
- Site 61 — Chicago, Illinois
- Site 53 — Clarksville, Indiana
- Site 55 — Plainfield, Indiana
- Site 79 — Leawood, Kansas
- Site 52 — Louisville, Kentucky
- Site 75 — New Orleans, Louisiana
- Site 84 — Glenn Dale, Maryland
- Site 87 — Rockville, Maryland
- Site 80 — Chestnut Hill, Massachusetts
- Site 59 — Quincy, Massachusetts
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Androgenetic Alopecia
- Safety and Efficacy of VDPHL01 in Males and Females With AGA — San Diego, California
- Use of Botulinum Toxin in the Treatment of Androgenic Alopecia — Edina, Minnesota
- Efficacy and Safety of VDPHL01 in Males With AGA — Birmingham, Alabama
- XVIE to Treat Androgenetic Alopecia (AGA) — Orlando, Florida
Explore by condition: All Androgenetic Alopecia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.